Senti Biosciences Unveils 60+ NOT-Gated CAR Designs with Improved Tumor Precision
Senti Biosciences published in Cell Systems a framework for engineering NOT-gated CAR circuits across 60+ designs, showing improved tumor targeting, reduced off-tumor activity and enhanced durability in T and NK cells. LIR1-based inhibitory CARs outperformed canonical checkpoints and demonstrated in vivo tumor clearance while sparing healthy cells in xenograft models.
1. Publication and Framework
Senti Biosciences detailed in Cell Systems a systematic framework for engineering NOT-gated CAR circuits by evaluating over 60 dual-receptor designs that integrate activating and inhibitory CARs. The publication establishes core design principles governing activation strength, inhibition dynamics, antigen dose response and functional durability.
2. Design Principles and Key Insights
Quantitative analysis identified optimal combinations of activating CARs for cancer killing and LIR1-based inhibitory CARs for healthy cell protection. LIR1 inhibitory receptors outperformed canonical immune checkpoints in reducing exhaustion markers and maintaining cytotoxic function after repeated antigen exposure.
3. In Vivo Efficacy
In a mixed-cell xenograft model, NOT-gated CAR T cells and CAR NK cells selectively eliminated tumor cells expressing target antigens while sparing off-tumor cells with protective markers. These results confirm the portability and effectiveness of logic-gated circuits in living subjects.
4. Gene Circuit Platform Impact
The findings validate Senti’s proprietary Gene Circuit platform for programming living medicines with decision-making capabilities. NOT-gated CAR circuits represent a foundational approach to enhance safety, expand the therapeutic window and apply synthetic biology across cell and gene therapies.